Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Sep 10;15(1):139.
doi: 10.1186/s12985-018-1050-3.

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Aoran Luo  1 , Xiaoyan Jiang  1 , Hong Ren  2
Affiliations
Meta-Analysis

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Aoran Luo et al. Virol J. .

Abstract

Background: Currently, there is no consensus on the efficacy and safety of lamivudine (LAM) plus tenofovir disoproxil fumarate (TDF) combination therapy versus lamivudine monotherapy in HBV/HIV coinfected patients.

Methods: A comprehensive literature search was performed in English and Chinese databases. Both relevant dichotomous and continuous variables were extracted, and the combined outcomes were expressed as a risk ratio (RR) or a standard mean difference (SMD).

Results: Eleven eligible studies were included in our analysis. For HBV-relevant outcomes, the proportion of patients with undetectable HBV, the rates of serum alanine aminotransferase (ALT) normalization and hepatitis B e antigen (HBeAg) loss were higher in the combination therapy group than the monotherapy group (RR = 1.42, 95% CI: 1.14-1.76, P = 0.002; RR = 1.36, 95% CI: 1.17-1.58, P < 0.0001; RR = 2.74, 95% CI: 1.20-6.22, P = 0.02). In addition, the rate of HIV RNA-negative conversion was higher in the combination therapy group than the monotherapy group (RR = 1.26, 95% CI: 1.11-1.42, P = 0.0003).

Conclusion: LAM plus TDF combination therapy was more efficacious than LAM monotherapy in HBV/HIV coinfected patients. As time passes, this difference becomes more pronounced.

Keywords: HBV/HIV coinfection; Lamivudine; Tenofovir.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

not applicable.

Consent for publication

not applicable.

Competing interests

The authors’ declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study selection process
Fig. 2
Fig. 2
Effect of LAM + TDF vs. LAM on HBV virologic response
Fig. 3
Fig. 3
Meta-regression of treatment duration (a), and subgroup analyses by 570 treatment duration (b)
Fig. 4
Fig. 4
Effect of LAM + TDF vs. LAM on HIV RNA Negative Conversion Rate
See this image and copyright information in PMC

References

    1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:6–9. doi: 10.1016/j.jhep.2005.11.004. - DOI - PubMed
    1. Kang L, Pan J, Wu J, Hu J, Sun Q, Tang J. Anti-HBV drugs: progress, unmet needs, and new hope. Viruses. 2015;7:4960–4977. doi: 10.3390/v7092854. - DOI - PMC - PubMed
    1. Diederich WE, Steuber H. Therapy of viral infections. Topics Med Chem. 2015;2:35–56.
    1. Fischer J. Analogue-based drug discovery. Chemistry International -- Newsmagazine for IUPAC. 2010;32:12–15.
    1. Sharp M, Interpharma D, Sharp M, Interpharma D, Celle L, Cloud S. Sharp M. WHO Model List of Essential Medicines: Interpharma D; 2011.

Publication types

MeSH terms